Gene therapy for hemoglobinopathies: the state of the field and the future [0.03%]
基因治疗血红蛋白病：现状与未来方向
Shanmuganathan Chandrakasan,Punam Malik
Shanmuganathan Chandrakasan
After nearly two decades of struggle, gene therapy for hemoglobinopathies using vectors carrying β or γ-globin gene has finally reached the clinical doorsteps. This was made possible by advances made in our understanding of critical regul...
Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain [0.03%]
镰状细胞贫血的缺血-再灌注损伤与急性胸部综合症、内皮功能障碍、动脉血管病和炎症性疼痛的关系
Robert P Hebbel
Robert P Hebbel
Ischemia-reperfusion (I/R) physiology, also called reperfusion injury, instigates vascular and tissue injury in human disease states. This review describes why sickle cell anemia should be conceptualized in this fashion and how I/R physiolo...
Frans A Kuypers
Frans A Kuypers
Different pathways lead from the simple point mutation in hemoglobin to the membrane changes that characterize the altered interaction of the sickle red blood cell with its environment, including endothelial cells, white blood cells, and pl...
Volker Diehl,Peter Borchmann
Volker Diehl
Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT? [0.03%]
复发/难治霍奇金淋巴瘤：最佳挽救性治疗方案以及是否需要RIC-alloSCT？
Mark Hertzberg
Mark Hertzberg
For relapsed-refractory Hodgkin Lymphoma, standard therapy consists of salvage chemotherapy followed by autologous stem cell transplantation. Adverse risk factors at relapse include response duration less than 12 months, advanced stage, ext...
Catherine Diefenbach,Ranjana Advani
Catherine Diefenbach
Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unravel...
FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? [0.03%]
FDG-PET指导的治疗反应个体化研究：18F-FDG PET能否安全地预测改变治疗？
Martin Hutchings
Martin Hutchings
Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is the most accurate tool for staging, treatment monitoring, and response evaluation in Hodgkin lymphoma (HL). Early determination of treatment sensitivity...
Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse) [0.03%]
晚期霍奇金淋巴瘤的诱导治疗：晚期强化方案（仅对复发患者采用ABVD化疗后接续大剂量化疗和自体干细胞移植）
Stephen M Ansell
Stephen M Ansell
The goal of therapy for patients with advanced-stage Hodgkin lymphoma is to ensure that as many patients as possible are healthy and free of disease decades after completing treatment. To achieve this, the treating physician needs to select...
Early intensification treatment approach in advanced-stage Hodgkin lymphoma [0.03%]
晚期霍奇金淋巴瘤早期强化治疗策略
Peter Borchmann
Peter Borchmann
The key question in advanced-stage Hodgkin lymphoma for many years now has been, should intensified chemotherapy be applied upfront or be reserved for relapsing patients. The early intensification approach with BEACOPP(escalated) (bleomycin...
Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone [0.03%]
适合度良好且处于早期霍奇金淋巴瘤患者的治疗风险与效益：仅采用多柔比星、博莱霉素、长春地辛和达卡巴嗪化疗的作用机制
Annette E Hay,Ralph M Meyer
Annette E Hay
Because long-term survival of patients with nonbulky stage IA to IIA Hodgkin lymphoma is dependent on disease control and avoidance of late toxic effects associated with the treatment received, the initial choice of treatment can be associa...